Associations between mild behavioral impairment and amyloid deposition in mild cognitive impairment
Poster No:
188
Submission Type:
Abstract Submission
Authors:
Eunjin Yoon1, Heejung Kim1, Jun-Young Lee1, Yu Kyeong Kim1
Institutions:
1Seoul National University, Seoul, Korea, Republic of
First Author:
Co-Author(s):
Introduction:
Mild behavioral impairment (MBI) is a validated neurobehavioral syndrome characterized by later life emergence of sustained neuropsychiatric symptoms. In our previous work, we found that amnestic mild cognitive impairment (aMCI) patients with multiple MBI domain symptoms (complex group) revealed a higher risk of progression to Alzheimer's disease compared with those with no MBI symptoms (asymptomatic group) or those with only affective dysregulation (affective dysregulation group) (Yoon et al, 2022). Here, we investigated whether the MBI subgroups associated with early amyloid deposition in aMCI individuals.
Methods:
A total 122 older adults with aMCI and 23 cognitively unimpaired (CU) individuals underwent 18F-florbetaben (FBB) PET scans. All participants were over 60 years of age. MBI was approximated using a transformation algorithm for the neuropsychiatric inventory and participants with aMCI were classified into asymptomatic, affective dysregulation, and complex groups. PET images were corrected partial volume effect (PVE) using modified Müller-Gärtner method (Rousset et al., 1998). Regional standardized uptake value ratio (SUVR) maps of FBB PET were calculated by dividing the mean of the cerebellar gray matter value. Each participant's FBB PET image was spatially normalized to template space using individual's T1-weighted MRI. Voxel-wise comparisons of FBB SUVR maps between groups (3 MBI groups and CU individuals) were performed using general linear model after controlling for age and sex (p < 0.05, FWE corrected ; k=100). Amyloid positivity was defined as Centiloid > 21. The conversion of FBB SUVR to Centiloid units was performed as previously described correction (Rowe et al., 2017) using the PET images without PVE correction.
Results:
The 3 MBI groups of aMCI individuals showed higher prevalence of amyloid-positive compared to CU individuals, however the prevalence of amyloid-positive was not significantly different between the MBI groups (asymptomatic, 53.1%; affective, 42.3%; complex, 48.4%; CU, 8.7%). Between 4 groups, there were no significant differences in age, sex, and years of education. In voxel-wise group comparisons, the complex group revealed higher FBB SUVRs in bilateral precuneus, inferior temporal gyrus and angular gyrus compared to CU individuals (Fig 1). The other MBI groups, the asymptomatic and affective dysregulation groups, did not revealed the significant differences with CU individuals in the same statistical level. There were also no significant group differences in FBB SUVRs between MBI groups.
·Fig 1. Brain regions showing higher amyloid deposition in the complex group compared to cognitively unimpaired individuals
Conclusions:
The multiple co-occuring MBI domain symptoms in aMCI individuals were associated with higher regional amyloid deposition, suggesting more advanced disease stage. Therefore, evaluation of MBI could be useful for risk stratification in MCI individuals.
Disorders of the Nervous System:
Neurodegenerative/ Late Life (eg. Parkinson’s, Alzheimer’s) 1
Lifespan Development:
Aging 2
Keywords:
Aging
Cognition
Degenerative Disease
Memory
Positron Emission Tomography (PET)
Other - Amyloid; Mild cognitive impairment; Mild behavioral impairment
1|2Indicates the priority used for review
Abstract Information
By submitting your proposal, you grant permission for the Organization for Human Brain Mapping (OHBM) to distribute your work in any format, including video, audio print and electronic text through OHBM OnDemand, social media channels, the OHBM website, or other electronic publications and media.
The Open Science Special Interest Group (OSSIG) is introducing a reproducibility challenge for OHBM 2025. This new initiative aims to enhance the reproducibility of scientific results and foster collaborations between labs. Teams will consist of a “source” party and a “reproducing” party, and will be evaluated on the success of their replication, the openness of the source work, and additional deliverables. Click here for more information. Propose your OHBM abstract(s) as source work for future OHBM meetings by selecting one of the following options:
Please indicate below if your study was a "resting state" or "task-activation” study.
Healthy subjects only or patients (note that patient studies may also involve healthy subjects):
Was this research conducted in the United States?
Were any human subjects research approved by the relevant Institutional Review Board or ethics panel? NOTE: Any human subjects studies without IRB approval will be automatically rejected.
Were any animal research approved by the relevant IACUC or other animal research panel? NOTE: Any animal studies without IACUC approval will be automatically rejected.
Please indicate which methods were used in your research:
For human MRI, what field strength scanner do you use?
Which processing packages did you use for your study?
Provide references using APA citation style.
Rowe, C.C., Dore, V., Jones, G., Baxendale, D., Mulligan, R.S., Bullich, S., Stephens, A.W, De Santi, S., Masters, C.L., Dinkelborg, L., & Villemagne, V.L. (2017). (18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids, Eur J Nucl Med Mol Imaging, 44(12), 2053-2059. doi.org/10.1007/s00259-017-3749-6
Yoon, E.J., Lee, J.Y., Kwak, S., & Kim, Y.K. (2022). Mild behavioral impairment linked to progression to Alzheimer's disease and cortical thinning in amnestic mild cognitive impairment. Front Aging Neurosci, 14, 1051621. doi:10.3389/fnagi.2022.1051621